Description

Descovy is a combination medication (tenofovir alafenamide/emtricitabine) considered to be the younger, sexier, and potentially safer sibling of Truvada (tenofovir disoproxil fumarate/emtricitabine) that is used for both HIV treatment and prevention. The emtricitabine (FTC) component of Descovy has been on the market since 2003, but tenofovir alafenamide (TAF) was only recently approved by the Food and Drug Administration (FDA): first, to be part of Descovy as part of a combination HIV treatment regimen, in 2016, then later as part of Descovy alone for HIV prevention, in 2019.